AC Immune's NLRP3 Inhibitor Shows Brain Penetration, Advances to Phase 1b
ACIU sits 24% above its 52-week low of $2.03.
Summary
AC Immune reported positive preliminary Phase 1 data for its oral NLRP3 inhibitor ACI-19764, showing safety, tolerability, and brain penetration in healthy volunteers. The drug achieved pharmacokinetic concentrations above the IC90 threshold at daily doses of 10mg or less and inhibited IL-1beta release in a dose-dependent manner. The trial has advanced to a Phase 1b cohort in patients at risk for cardiovascular disease, with initial findings expected before year-end. This follows the company's recent FDA Fast Track designation for its Parkinson's immunotherapy ACI-7104, underscoring momentum across its wholly-owned pipeline. The stock traded down 4.26% at $2.47 on the news, reflecting a muted market reaction despite the positive data.
At the time of this announcement, ACIU was trading at $2.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $257M. The 52-week trading range was $2.03 to $4.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.